EV
EVFM.US Evofem Biosciences Inc
- Market cap
- USD 769K
- P/E
- -
- P/B
- 8.37x
- ROE
- -
- Dividend yield
- 15.22%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EVFM.US undervalued?
Graham numberThe Graham number of Evofem Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evofem Biosciences Inc fundamental analysis
No fundamental analysis for Evofem Biosciences Inc yet.
Evofem Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evofem Biosciences Inc
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Full company profileEvofem Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Evofem Biosciences Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 446K | 8.24M | 16.8M | 18.2M | 19.4M | 20.2M | - |
| Gross Profit | -69.1K | -244K | -262K | -905K | -1.20M | 4.19M | 12.4M | 11.7M | 15.5M | 15.1M | - |
| Operating Income | -12.0M | -35.7M | -77.6M | -52.7M | -104M | -167M | -84.1M | -17.8M | -7.68M | 1.44M | -8.42M |
| EBITDA | -11.9M | -105M | -125M | -79.1M | -141M | -166M | -82.1M | -16.1M | -6.92M | 2.07M | -8.21M |
| Net Income | -13.0M | -105M | -126M | -80.0M | -142M | -205M | -76.7M | 53.0M | -8.86M | 391K | -20.9M |
| EPS | -10,610 | -85,614 | -10,763 | -3,730 | -3,973 | -2,939 | -165 | 0.05 | -0.09 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 12.8M | 3.95M | 4.01M | 28.3M | 110M | 42.5M | 25.2M | 10.6M | 23.8M | 20.3M | 7.26M |
| Total Liabilities | 902K | 104M | 27.4M | 12.7M | 109M | 142M | 97.0M | 77.1M | 95.0M | 89.7M | 86.0M |
| Shareholders' Equity | 11.9M | -99.7M | -23.4M | 15.6M | 1.35M | -99.6M | -71.8M | -66.5M | -71.3M | -69.4M | -78.8M |
| Cash & Short-term Investments | 11.5M | 1.70M | 1.76M | 24.1M | 71.5M | 7.73M | 2.77M | 580K | 741K | 578K | 317K |
| Total Debt | - | - | 4.01M | 197K | 85.9M | 116M | 71.1M | 43.4M | 46.0M | 54.5M | 70.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.3M | -19.2M | -56.5M | -55.1M | -106M | -147M | -70.4M | -8.97M | -3.89M | -1.99M | -833K |
| Capital Expenditure | 3.00 | 6.00K | 7.00K | 164K | 2.25M | 2.94M | 341K | 4.00K | 14.0K | 5.00K | 2.67K |
| Free Cash Flow | -16.3M | -19.2M | -56.5M | -55.3M | -108M | -150M | -70.8M | -8.97M | -3.90M | -2.00M | -836K |
| Ratios | |||||||||||
| ROE | -109.3% | - | - | -511.9% | -10,564.9% | - | - | - | - | - | - |
| ROA | -101.6% | -2,664.6% | -3,135.0% | -282.9% | -129.4% | -482.7% | -304.8% | 502.0% | -37.2% | 1.9% | -287.5% |
| Net Profit Margin | - | - | - | - | -31,907.8% | -2,489.0% | -455.5% | 290.8% | -45.8% | 1.9% | - |
| Debt to Equity | - | - | - | 0.01x | 63.80x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Evofem Biosciences Inc dividends
- Dividend yield
- 15.22%
- Forward dividend
- -
- Payout ratio
- 29.9%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 117K | 0.00 | 29.9% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 75.4M | 3,514 | - |
| 2018 | USD 157K | 13 | - |
| 2017 | USD 157K | 128 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:125 on May 18, 2023.
Who owns Evofem Biosciences Inc
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 133M
- Free float 133M
Top funds holding EVFM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| NT Quality Small Cap Core | 127.00 | 0.00% | 0.00% | Mar 2023 |
| NT Quality SCC US Fund - L | 127.00 | 0.00% | 0.00% | Mar 2023 |
Top institutions holding EVFM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Laffer Tengler Investments, Inc. | 0.00 | 0.00% | -100.00% | Dec 2022 |
| CLEAR STREET LLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| IFP Advisors, LLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Activest Wealth Management | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Barclays PLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Westside Investment Management, Inc. | 0.00 | 0.00% | -100.00% | Dec 2022 |
Evofem Biosciences Inc company profile
- Company name
- Evofem Biosciences Inc
- Ticker
- EVFM.US
- Exchange
- USA Stocks
- Listed since
- Jan 17, 2018
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 29
- Fiscal year end
- December
- Address
- 7770 Regents Rd, San Diego, CA, United States, 92122-1967
- Phone
- 858 550 1900
- Website
- evofem.com
About Evofem Biosciences Inc
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Evofem Biosciences Inc management
4- Ms. Saundra PelletierInterim Chair, President & CEO · born 1970
- Ms. Ivy Zhang CPACFO & Secretary · born 1979
- Ms. Ellen ThomasChief of Staff
- Ms. Amy RaskopfChief Business Development Officer